诱导多能干细胞治疗缺血性卒中：现状和挑战  

Induced pluripotent stem cells for the treatment of ischemic stroke：current status and challenges

作　　者：李芸[1] 杨恋[1] 王昭君[1] 徐格林[1] 刘亚红[1] 

机构地区：[1]南京军区南京总医院神经内科,210002

出　　处：《国际脑血管病杂志》2014年第11期877-880,共4页International Journal of Cerebrovascular Diseases

基　　金：国家自然科学基金（31200817;31171016;31100784）

摘　　要：近年来,干细胞移植用于治疗缺血性卒中成为研究热点.然而,由于胚胎干细胞（embryonic stem cell,ESC）移植受到伦理和法律的限制,干细胞研究一度陷入困境.诱导多能干细胞（induced pluripotent stem cell,iPSC）是通过将特定的转录因子导入体细胞而产生的一类细胞,其具有与ESC相似的特征,而且回避了伦理问题和免疫排斥反应,使得其成为最理想的ESC替代者.尽管目前关于iPSC的研究已取得一定的进展,但其诱导效率和安全性问题仍有待解决.文章就iPSC移植治疗缺血性卒中的现状、机制及其在临床应用中面临的问题进行了综述.In recent years,stem cell transplantation for the treatment of ischemic stroke has become a hot topic.However,since embryonic stem cells （ESCs） transplantation is limited by the ethics and law,stem cell research was once in trouble.Induced pluripotent stem cells （iPSCs） are a class of cells by introducing the specific transcription factors into somatic cells,which have the similar characteristics with ESCs,and also avoid the ethical issues and immunological rejection,making them become the most ideal replacer of ESCs.Although the current research on iPSCs has made some progress,their induction efficiency and safety issues remain to be resolved.This article reviews the status quo,mechanisms,and problems faced in clinical practice for iPSCs transplantation in the treatment of ischemic stroke.

关 键 词：卒中 脑缺血 诱导多功能干细胞 干细胞移植 

分 类 号：R743.3[医药卫生—神经病学与精神病学]